Nurix Therapeutics
NRIX | NASDAQ
$14.73
-$0.75 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$14.92
+$0.19 (+1.29%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Nurix Therapeutics Company Profile
Company profile explainedCompany Profile
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Key Executives
| Name | Position |
|---|---|
| Arthur T. Sands | Chief Executive Officer, President & Director |
| Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer |
| Johannes Van Houte | Chief Financial Officer |
| Arthur Weiss | Founder & Member of Scientific Advisory Board |
| Gwenn Hansen | Chief Scientific Officer |
| Jason Kantor | Chief Business Officer |
| John Kuriyan | Founder & Member of Scientific Advisory Board |
| Pasit Phiasivongsa | Chief Technical Officer |
| Rita Kwong | Senior Accounting Manager |
| Wesley Burwell | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 13, 2026 | 10-Q | Quarterly Report |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Sep 23, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 02, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nurix Therapeutics
| Country | United States |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 317 |
| CEO | Arthur T. Sands |
Contact Details
1600 Sierra Point Parkway Brisbane,
California 94005 United States
Stock Details
| Ticker Symbol | NRIX |
| Exchange | NASDAQ |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| CIK Code | 0001549595 |
| CUSIP Number | 67080M103 |
| ISIN Number | US67080M1036 |
| SIC Code | 2834 |
Recent News
- 5 days ago / globenewswire.comNurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
- 6 days ago / globenewswire.comNurix Therapeutics to Participate in Upcoming Investor Conferences
- 1 month ago / seekingalpha.comNurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
- 1 month ago / zacks.comNurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
- 1 month ago / globenewswire.comNurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 1 month ago / globenewswire.comNurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
- 1 month ago / globenewswire.comNurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
- 2 months ago / seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
- 2 months ago / seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / zacks.comHere's Why You Should Add NRIX Stock to Your Portfolio Now
Add to Watchlist
Select watchlists to add or remove NRIX